Correlation Between Cadrenal Therapeutics, and Puma Biotechnology

Can any of the company-specific risk be diversified away by investing in both Cadrenal Therapeutics, and Puma Biotechnology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Cadrenal Therapeutics, and Puma Biotechnology into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Cadrenal Therapeutics, Common and Puma Biotechnology, you can compare the effects of market volatilities on Cadrenal Therapeutics, and Puma Biotechnology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Cadrenal Therapeutics, with a short position of Puma Biotechnology. Check out your portfolio center. Please also check ongoing floating volatility patterns of Cadrenal Therapeutics, and Puma Biotechnology.

Diversification Opportunities for Cadrenal Therapeutics, and Puma Biotechnology

-0.35

Correlation Coefficient

Cadrenal Therapeutics,  Puma Biotechnology

Very good diversification

The 3 months correlation between Cadrenal and Puma is -0.35. Overlapping area represents the amount of risk that can be diversified away by holding Cadrenal Therapeutics, Common and Puma Biotechnology in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Puma Biotechnology and Cadrenal Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Cadrenal Therapeutics, Common are associated (or correlated) with Puma Biotechnology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Puma Biotechnology has no effect on the direction of Cadrenal Therapeutics, i.e., Cadrenal Therapeutics, and Puma Biotechnology go up and down completely randomly.

Pair Corralation between Cadrenal Therapeutics, and Puma Biotechnology

Given the investment horizon of 90 days Cadrenal Therapeutics, Common is expected to generate 0.97 times more return on investment than Puma Biotechnology. However, Cadrenal Therapeutics, Common is 1.03 times less risky than Puma Biotechnology. It trades about 0.08 of its potential returns per unit of risk. Puma Biotechnology is currently generating about 0.03 per unit of risk. If you would invest  1,645  in Cadrenal Therapeutics, Common on December 25, 2024 and sell it today you would earn a total of  279.00  from holding Cadrenal Therapeutics, Common or generate 16.96% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Cadrenal Therapeutics, Common  vs.  Puma Biotechnology

Cadrenal Therapeutics,

Risk-Adjusted Performance

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Cadrenal Therapeutics, Common are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of rather uncertain forward-looking signals, Cadrenal Therapeutics, exhibited solid returns over the last few months and may actually be approaching a breakup point.

Puma Biotechnology

Risk-Adjusted Performance

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Puma Biotechnology are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite fairly unsteady basic indicators, Puma Biotechnology may actually be approaching a critical reversion point that can send shares even higher in April 2025.

Pair Trading with Cadrenal Therapeutics, and Puma Biotechnology

The main advantage of trading using opposite Cadrenal Therapeutics, and Puma Biotechnology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Cadrenal Therapeutics, position performs unexpectedly, Puma Biotechnology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Puma Biotechnology will offset losses from the drop in Puma Biotechnology's long position.

The idea behind Cadrenal Therapeutics, Common and Puma Biotechnology pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.